VRDN Stock: Price, Earnings History and SEC Filings
Viridian Therapeutics, Inc. (VRDN) last traded at $24.67, down 0.52% on the latest session and up 19.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.05 against an analyst estimate of $-0.97, a miss of 8.2%.
$24.67 -0.52%
1 month+19.82%
52-week high$34.29
52-week low$13.18
Volume1.71M
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VRDN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-1.05 | $-0.97 | -8.25% |
| Mar 2026 | May 5, 2026 | $-0.90 | $-1.06 | +15.09% |
| Dec 2025 | Feb 26, 2026 | $-1.08 | $-0.90 | -20.00% |
| Sep 2025 | Nov 5, 2025 | $-0.34 | $-0.82 | +58.54% |
VRDN beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for VRDN
SEC filing data is not available right now. You can search for VRDN on SEC EDGAR.
VRDN news
- How FDA Approval Will Impact Viridian Therapeutics StockOct 27, 2026 · finance.yahoo.com
- Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026Oct 20, 2026 · finance.yahoo.com
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (VRDN) is a US-listed public company on Nasdaq.